Royal Society
6-9 Carlton House Terrace
London
SW1Y 5AG
The Coalition Government has set out an ambitious program of radical change in the NHS. The aim is to reduce management costs by 45% while putting the patient, GPs and clinicians at the centre of the new NHS structure. Both PCTs and Strategic Health Authorities will be abolished and replaced by new GP consortia that will have new responsibilities for commissioning. At the same time, significant changes to the way in which medicines will be priced and reimbursed are encompassed in proposals for Value Based Pricing. NICE will have new responsibilities and powers, especially in areas such as quality standards. The Government has also established an interim Cancer Drug Fund aimed at improving the treatment of cancer care.
These changes will have a significant impact on the UK industry, particularly in R&D, access and uptake of new medicines. Value based pricing will apply to all new product launches and represents the biggest upheaval to drug pricing in the UK for 50 years. Apart from improving patient outcomes and ensuring value for money, a central aim of VBP is to stimulate innovation and the development of high value treatment away from perceived me-too therapies. The impact of such a policy could have a significant effect on company R&D pipelines and the way future R&D is carried out in the UK.
This joint BIA/EMIG Conference on 24 May in central London will explore in detail the Government’s current health reform program, and will cover new commissioning pathways, the changing role of NICE and its possible role in value based pricing, the current status of the Cancer Drug Fund, and how the QIPP agenda is being used to implement greater quality and efficiency against a backdrop of savings of £20 billion in the next four years.
For further information please see the website:
https://www.bioindustry.org/cgi-bin/events.pl?CD=4448
